Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus

Trial Profile

A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol/progesterone (Primary)
  • Indications Menopausal syndrome; Vasomotor symptoms
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms REPLENISH
  • Sponsors TherapeuticsMD
  • Most Recent Events

    • 14 Feb 2022 Results (n=157) assessing bone turnover markers (BTM) in this trial, published in the Menopause.
    • 25 May 2021 According to a TherapeuticsMD media release, If FDA accepted the sNDA, the company expects that the review time under the Prescription Drug User Fee Act (PDUFA) will be within ten months of receipt by the FDA, approximately March 21, 2022.
    • 27 Apr 2020 Results (n=157) of post-hoc analysis assessing bone turnover markers in women with Vasomotor Symptoms, presented at the 69th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top